VFMCRP- ChemoCentryx announce topline data from Phase 2 LUMINA-1 trial

Date: 2020-05-18   Author: Saipriya Iyer  Category: #news

VFMCRP- ChemoCentryx announce topline data from Phase 2 LUMINA-1 trial

VFMCRP (Vifor Fresenius Medical Care Renal Pharma) & ChemoCentryx, Inc. have recently announced the topline data from its 46 patient Phase 2 dose-ranging trial. The trial has been conducted for the orphan kidney disease, primary FSGS (Focal Segmental Glomerulosclerosis).

The trial has tested a CCR2 (the chemokine receptor) selective inhibitor that was orally administered, namely CCX140, in the primary FSGS subjects. The inhibitor did not exhibit a meaningful proteinuria reduction during the trial, in relation to control group following the 12-week blinded treatment.

The primary efficacy measure of the LUMINA-1 trial was a change observed in proteinuria, which is measured by UPCR (urine protein to the creatinine ratio), in 4 groups of blinded treatment (3 active CCX140 doses v/s 1 placebo) from the baseline to 12th week. In the 12th week, all subjects, which include those receiving the placebo, were treated with the CCX140 highest dose. 15 mg of CCX140 twice a day was also offered for an extra 12 weeks of the treatment. Following this, UPCR changes from the week 12th to week 24th have been assessed.

The 15mg dose of CCX140 has exhibited the highest UPCR reduction in the ITT (intent to treat) analysis of the changes of UPCR at week 12 relative to the baseline. The reduction of median from the baseline by over 30% or 0.9 g/g has been observed, with the reduction from the baseline by nearly 25% for geometric mean. Additionally, after the crossover of the blinded portion of this study to 15mg BID dosing, there was no additional UPCR reduction by the previous group of the placebo.

CCX140 was well-tolerated at various doses, with no SAEs (serious adverse events) in the blinded study. It has a numerically lower adverse event rate that emerged from the treatment in the CCX140 group as compared to the placebo group. The complete analysis of the data for the recent trial is in progress, with the expanded results anticipated to be revealed at the medical meeting in 2020.

Source credit:https://www.businesswire.com/news/home/20200517005052/en/VFMCRP-ChemoCentryx-announce-topline-data-phase-II-LUMINA-1



About Author


Saipriya Iyer linkdin-boxtwitter

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

Post Recommendents

Antenatal Screening Market Share, By Product Analysis, Application, End-Use, Regional Outlook, Competitive Strategies & Forecast up to 2028

Author: Ashwin Naphade

Global Antenatal Screening Market, 2022-2028 Research Report provides crucial statistics on the market status of the Global Antenatal Screening manufacturers and is a respected source of guidance and direction for companies and individuals interes...


Pediatric Vitrectomy Market Size | Global Industry Analysis, Segments, Top Key Players, Drivers and Trends to 2028

Author: Ashwin Naphade

Global Pediatric Vitrectomy market report provides major statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

The Pediatric Vitrectomy market repor...


Legionnaire Disease Testing Market Comprehensive Analysis, Share, Growth Forecast from 2022 to 2028c

Author: Ashwin Naphade

This report studies the Global Legionnaire Disease Testing market status and outlook of global and major regions, from angles of players, regions, product types and end industries; this report analyzes the top players in global and major regions, ...